Literature DB >> 16377709

The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.

Neil T Parkin1, Soumi Gupta, Colombe Chappey, Christos J Petropoulos.   

Abstract

Genotypic patterns associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in the absence of well-characterized resistance mutations were identified using a database (n > 47,000) of phenotype-genotype data. Among samples with no known NNRTI mutations, the most resistant samples contained K101P (n = 35) or a combination of K103R and V179D (n = 41). Site-directed mutagenesis confirmed the importance of these mutations.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16377709      PMCID： PMC1346823          DOI： 10.1128/AAC.50.1.351-354.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.

Authors:  Mercedes Muñoz; Rocío Carmona; Lucía Pérez-Alvarez; Gustavo Cilla; María Dolores Suarez; Elena Delgado; Gerardo Contreras; Jesús Corral; María José López de Goicoetxea; Leandro Medrano; María Jesús Lezaún; Rafael Nájera
Journal:  J Clin Virol       Date:  2005-01-12       Impact factor: 3.168

2.  The "megaprimer" method of site-directed mutagenesis.

Authors:  G Sarkar; S S Sommer
Journal:  Biotechniques       Date:  1990-04       Impact factor: 1.993

3.  Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells.

Authors:  Loredana Sarmati; Emanuele Nicastri; Saverio G Parisi; Gabriella d'Ettorre; Giorgio Mancino; Pasquale Narciso; Vincenzo Vullo; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  P Richard Harrigan; Theresa Mo; Brian Wynhoven; Jennifer Hirsch; Zabrina Brumme; Paula McKenna; Theresa Pattery; Johan Vingerhoets; Lee T Bacheler
Journal:  AIDS       Date:  2005-03-24       Impact factor: 4.177

5.  Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

Authors:  J H Nunberg; W A Schleif; E J Boots; J A O'Brien; J C Quintero; J M Hoffman; E A Emini; M E Goldman
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

Authors:  Patrick G Yeni; Scott M Hammer; Martin S Hirsch; Michael S Saag; Mauro Schechter; Charles C J Carpenter; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

7.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.

Authors:  D D Richman; D Havlir; J Corbeil; D Looney; C Ignacio; S A Spector; J Sullivan; S Cheeseman; K Barringer; D Pauletti
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  S D Young; S F Britcher; L O Tran; L S Payne; W C Lumma; T A Lyle; J R Huff; P S Anderson; D B Olsen; S S Carroll
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1.

Authors:  N T Parkin; N S Hellmann; J M Whitcomb; L Kiss; C Chappey; C J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  J P Kleim; R Bender; R Kirsch; C Meichsner; A Paessens; G Riess
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616
View more
  17 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

3.  Use of tissue culture cell lines to evaluate HIV antiviral resistance.

Authors:  Halina Krowicka; James E Robinson; Rebecca Clark; Shannon Hager; Stephanie Broyles; Seth H Pincus
Journal:  AIDS Res Hum Retroviruses       Date:  2008-07       Impact factor: 2.205

4.  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Authors:  George L Melikian; Soo-Yon Rhee; Vici Varghese; Danielle Porter; Kirsten White; Jonathan Taylor; William Towner; Paolo Troia; Jeffrey Burack; Edwin Dejesus; Gregory K Robbins; Kristin Razzeca; Ron Kagan; Tommy F Liu; W Jeffrey Fessel; Dennis Israelski; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2013-08-09       Impact factor: 5.790

5.  Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.

Authors:  Rajin Shahriar; Soo-Yon Rhee; Tommy F Liu; W Jeffrey Fessel; Anthony Scarsella; William Towner; Susan P Holmes; Andrew R Zolopa; Robert W Shafer
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

6.  Mining protein dynamics from sets of crystal structures using "consensus structures".

Authors:  Gerard J P van Westen; Jörg K Wegner; Andreas Bender; Adriaan P Ijzerman; Herman W T van Vlijmen
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

7.  Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.

Authors:  William T Gray; Kathleen M Frey; Sarah B Laskey; Andrea C Mislak; Krasimir A Spasov; Won-Gil Lee; Mariela Bollini; Robert F Siliciano; William L Jorgensen; Karen S Anderson
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

8.  Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).

Authors:  William Ian Towler; Jessica D Church; James R Eshleman; Mary Glenn Fowler; Laura A Guay; J Brooks Jackson; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

9.  Bayesian network analyses of resistance pathways against efavirenz and nevirapine.

Authors:  Koen Deforche; Ricardo J Camacho; Zehave Grossman; Marcelo A Soares; Kristel Van Laethem; David A Katzenstein; P Richard Harrigan; Rami Kantor; Robert Shafer; Anne-Mieke Vandamme
Journal:  AIDS       Date:  2008-10-18       Impact factor: 4.177

Review 10.  Avoiding Drug Resistance in HIV Reverse Transcriptase.

Authors:  Maria E Cilento; Karen A Kirby; Stefan G Sarafianos
Journal:  Chem Rev       Date:  2021-01-28       Impact factor: 60.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.